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ABSTRACT
Impaired PTEN function is a genetic hallmark of aggressive prostate cancers 
(CaP) and is associated with increased CXCL8 expression and signaling. The current 
aim was to further characterize biological responses and mechanisms underpinning 
CXCL8-promoted progression of PTEN-depleted prostate cancer, focusing on 
characterizing the potential interplay between CXCL8 and other disease-promoting 
chemokines resident within the prostate tumor microenvironment. Autocrine CXCL8-
stimulation (i) increased expression of CXCR1 and CXCR2 in PTEN-deficient CaP cells 
suggesting a self-potentiating signaling axis and (ii) induced expression of CXCR4 and 
CCR2 in PTEN-wild-type and PTEN-depleted CaP cells. In contrast, paracrine CXCL8 
signaling induced expression and secretion of the chemokines CCL2 and CXCL12 
from prostate stromal WPMY-1 fibroblasts and monocytic macrophage-like THP-1 
cells. In vitro studies demonstrated functional co-operation of tumor-derived CXCL8 
with stromal-derived chemokines. CXCL12-induced migration of PC3 cells and CCL2-
induced proliferation of prostate cancer cells were dependent upon intrinsic CXCL8 
signaling within the prostate cancer cells. For example, in co-culture experiments, 
CXCL12/CXCR4 signaling but not CCL2/CCR2 signaling supported fibroblast-mediated 
migration of PC3 cells while CXCL12/CXCR4 and CCL2/CCR2 signaling underpinned 
monocyte-enhanced migration of PC3 cells. Combined inhibition of both CXCL8 and 
CXCL12 signaling was more effective in inhibiting fibroblast-promoted cell motility 
while repression of CXCL8 attenuated CCL2-promoted proliferation of prostate cancer 
cells. We conclude that tumor-derived CXCL8 signaling from PTEN-deficient tumor 
cells increases the sensitivity and responsiveness of CaP cells to stromal chemokines 
by concurrently upregulating receptor expression in cancer cells and inducing stromal 
chemokine synthesis. Combined chemokine targeting may be required to inhibit their 
multi-faceted actions in promoting the invasion and proliferation of aggressive CaP.
INTRODUCTION
Large scale sequencing and molecular pathology 
analysis is providing deeper insight into the genetic 
underpinnings of prostate cancer, heightening anticipation 
of near-term and widespread access to precision-
based therapy of prostate cancer [1]. One of the best 
characterized common genetic events in prostate cancer 
relates to the impaired function of PTEN, a haplo-
insufficient tumor suppressor gene, whose primary 
cellular activity is to regulate the phosphatidylinositol-
3-kinase (PI3K)/Akt signaling pathway. Allelic loss, 
epigenetic silencing and/or acquisition of functionally-
inactivating mutations have all been shown to contribute 
to the impairment of PTEN in prostate cancer [2,3]. 
Elegant in vivo genetically-engineered mouse models 
have shown that heterozygous or homozygous deletion 
of PTEN in the prostate epithelium [4] or alternatively, 
constitutive activation of the downstream effector PKB/
Akt [5] underpins the development of a prostate pathology 
recapitulating human prostatic intra-epithelial neoplasia 
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(PIN), a pre-malignant condition. In further experimental 
models, the combination of PTEN loss with ERG over-
expression or Tp53 mutation has been shown to promote 
the transition to invasive prostate carcinoma [6,7] while 
epidemiological studies conform the relevance of PTEN to 
aggressive prostate cancer [8]. In support of this, a recently 
published longitudinal molecular pathology analysis 
indicated that mutation of PTEN was associated with 
the lethal phenotype of prostate cancer [9]. Furthermore, 
other recent studies support that functional loss of PTEN is 
correlated with the relapse of prostate cancer after radical 
prostatectomy or radiotherapy [10,11]. Therefore, while 
pre-clinical and clinical evidence suggests that increased 
signaling of the PTEN/PI3K/Akt pathway is considered to 
be a sustaining drive in the development and progression 
of this disease, our understanding of the key biological 
mediators and microenvironment responses that underpin 
and define the more aggressive behavior of PTEN-depleted 
prostate cancer remains to be fully defined. 
Chemokines are critical signaling mediators, driving 
communication between malignant epithelial cells and the 
surrounding microenvironment, and contribute to multiple 
hallmarks of cancer. Overexpression and increased 
activity of three specific chemokines termed CCL2, 
CXCL12 and CXCL8 have been strongly implicated 
in the progression of prostate cancer [12-14]. Increased 
expression and activity of CCL2 and CXCL12 has been 
reported in both the localized prostate cancer and within 
the microenvironment of bone metastases [13-18], while 
prior work from our own group has confirmed elevated 
CXCL8 expression in human prostate cancer tissue [19]. 
Our recent research has established an important 
contextual relationship of impaired PTEN function to 
the over-expression of CXCL8 in prostate tumor cells. 
Conversely, modulation of this tumor suppressor gene had 
no impact on the expression of either CCL2 or CXCL12 
in prostate cancer cells [20]. Other studies report that 
expression of CCL2 and CXCL12 may originate from 
stromal cells and regulate tumor cell behavior through 
promotion of paracrine signaling [12,13,15,18,21]. 
Therefore, the initial objective of this study was to 
establish the existence of interplay between tumor-derived 
CXCL8 from PTEN-deficient prostate cancer cells and 
the potentiation of stromal-derived CCL2 and CXCL12 
expression and/or signaling. Our further objective was to 
characterize the functional consequences of this interplay 
in the context of augmenting the proliferation and/or 
migration of PTEN-deficient prostate cancer cells. In this 
study, we report a co-operative role between CXCL8 and 
stromal-derived chemokines, establishing a multi-faceted 
chemokine cross-talk between PTEN-deficient tumor 
and stroma that sustains the proliferation, migration and 
invasion of these aggressive prostate cancer cells. 
RESULTS
CXCL8 signaling regulates chemokine receptor 
expression in the prostate epithelium 
Our prior studies demonstrated that silencing 
of PTEN expression increased the transcription and 
secretion of CXCL8 and increased gene expression of the 
receptors CXCR1 and CXCR2 in prostate cancer cells 
[20]. In the current study, our initial experiments sought to 
investigate how elevated levels of CXCL8 signaling may 
regulate chemokine receptor expression in the prostate 
epithelium. The ability of the recombinant-human CXCL8 
(rh-CXCL8) stimulus to regulate chemokine receptor 
expression was studied in representative androgen-
sensitive (LNCaP and 22Rv1) and castrate-resistant 
(PC3 and DU145) cell lines. QPCR analysis confirmed 
that exogenous rh-CXCL8 administration significantly 
increased CXCR1 (Fig 1A, left panel) and CXCR2 (Fig 
1A, right panel) mRNA expression in the PTEN-null 
PC3 and LNCaP cells. No change in CXCR1 or CXCR2 
mRNA expression was detected in PTEN-expressing 
DU145 or 22Rv1 cells (Fig 1A). The importance of PTEN 
in regulating this response was exemplified using isogenic 
lines. Administration of rh-CXCL8 induced CXCR1/2 
mRNA expression in a PTEN-depleted clone (sh11.02) 
but not a PTEN-expressing (NT.01) clone of the DU145 
cell line (Figure S1A). Furthermore, immunoblotting 
confirmed the CXCL8-stimulated increase in CXCR1 
and CXCR2 receptor expression in PC3 and LNCaP cells 
(Fig 1B). Therefore, these initial experiments suggest 
that CXCL8 signaling can potentiate expression of the 
receptors transducing its biological activity in PTEN-
deficient prostate carcinoma cells. 
The effect of CXCL8 on expression of CCR2 
and CXCR4 was also investigated. Stimulation with 
rh-CXCL8 increased CCR2 mRNA expression in both 
castrate-resistant cell lines, irrespective of their PTEN 
status (Fig 1C, left panel), and in each of the androgen-
sensitive lines, LNCaP and 22Rv1 (Fig 1C, left panel). 
Similarly, rh-CXCL8 signaling increased CXCR4 mRNA 
levels in all four cell lines relative to un-stimulated 
controls (Fig 1C, right panel). Furthermore, QPCR 
analysis demonstrated that the magnitude of increased 
CCR2 and CXCR4 mRNA expression was similar in the 
isogenic DU145 11.02 and NT.01 clones, supporting that 
CXCL8-induced regulation of these chemokine receptors 
is independent of PTEN expression (Fig S1B). We also 
determined that CXCL8 signaling increased CXCR7 
mRNA expression, a further receptor shown to mediate the 
biological activity of CXCL12 (Fig S1C). QPCR data was 
confirmed by immunoblotting analysis, which confirmed 
CXCL8-induced up-regulation of CXCR4 receptor protein 
expression in PC3 and LNCaP cells (Fig 1B). Therefore, 
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our data indicates that CXCL8 signaling originating from 
PTEN-deficient tumor cells increases the expression of 
CCR2 and CXCR4 in prostate epithelium, but of potential 
significance, we observed that the expression of these 
receptors can be induced in prostate epithelial cells that 
still retain functional PTEN and have the capacity to 
respond to CXCL8.
CXCL8 signaling regulates CCL2 and CXCL12 
expression and secretion in prostate stromal cells 
Further experiments focused on characterizing the 
regulation of CXCL12 and CCL2 across our panel of 
prostate cancer cells and representative stromal cell lines. 
Basal mRNA expression for CCL2 (Fig 2A, left panel) 
and CXCL12 (Fig 2A, right panel) was lower in each of 
the prostate cancer cell lines relative to the expression 
detected in the WPMY-1 prostate stromal fibroblast or 
the monocytic THP-1 cell lines. Furthermore, qPCR 
analysis revealed no change in CXCL12 (Fig S2A) or 
CCL2 (Fig S2B) mRNA expression following stimulation 
with rh-CXCL8 in any of the prostate cancer cell lines 
studied; moreover, we observed that the secretion of either 
CCL2 or CXCL12 from any of the prostate cancer cells 
was below the limits of detection of the ELISA assays 
employed. However, basal secretion of these chemokines 
from the representative stromal cell lines was easily 
detectable (Fig S2C). 
Figure 1: Autocrine CXCL8 signaling increases chemokine receptor expression in prostate cancer cells. (A) Bar graph 
illustrating qPCR validation of CXCR1 (left panel) and CXCR2 (right panel) gene expression in multiple prostate cancer cell lines, 
subjected to stimulation with 3nM rh-CXCL8. (B) Immunoblots demonstrating increased protein levels of chemokine receptors in PC3 
(left panel) and LNCaP cells (right panel) following exposure to 3nM rh-CXCL8. (C) Bar graph illustrating qPCR validation of CCR2 (left 
panel) and CXCR4 (right panel) gene expression in multiple prostate cancer cell lines, subjected to stimulation with 3nM rh-CXCL8. Data 
shown in (A) and (C) is the mean ± S.E.M value, determined from a minimum of 4 replicate experiments. Statically significant differences 
in expression were determined by performing a two-tailed Mann-Whitney U-test (*p<0.05; ** p<0.01; ***p<0.001). 
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Figure 2: Paracrine CXCL8 signaling induces CCL2 and CXCL12 synthesis and secretion in stromal cells. (A) Bar graph 
illustrating qPCR validation of CCL2 (left panel) and CXCL12 (right panel) gene expression in multiple prostate cancer and stromal cell 
lines. (B) Bar graph illustrating qPCR validation of CCL2 (left panel) and CXCL12 (right panel) gene expression in THP-1 macrophage-
like cells, 293T and WPMY-1 stromal fibroblasts, subjected to stimulation with 3nM rh-CXCL8. (C) Bar graph illustrating the levels of 
CCL2 (left panel) and CXCL12 (right panel) secreted by stromal cells, in the absence and presence of stimulation with 3nM rh-CXCL8. 
Data shown represents the mean ± S.E.M. value determined by repetitive ELISAs. (D) Bar graph illustrating qPCR validation of CCR2 (left 
panel) and CXCR4 (right panel) gene expression in stromal THP-1 cells, 293T cells and WPMY-1 cells subjected to stimulation with 3nM 
rh-CXCL8. Data shown in (A), (B) and (D) is the mean ± S.E.M value, determined from a minimum of 4 replicate experiments. Statically 
significant differences in expression were determined by performing a two-tailed Mann-Whitney U-test (*p<0.05; ** p<0.01; ***p<0.001). 
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Expression of CXCR1 and CXCR2 was also 
detected in the stromal cell lines and this was up-regulated 
in response to CXCL8 stimulation, demonstrating 
their responsiveness to CXCL8 stimulation (Fig S2D). 
Moreover, we observed a significant increase in CCL2 
mRNA expression (Fig 2B, left panel) and secretion (Fig 
2C, left panel) from macrophage-like THP-1 cells as well 
as WPMY-1 and 293T cells (both fibroblast-like cell lines) 
following exposure to rh-CXCL8. Increased CXCL12 
mRNA expression was detected to varying degrees in 
CXCL8-stimulated THP-1, 293T and WPMY-1 cells 
(Fig 2B, left panel). CXCL12-secretion was significantly 
increased from both fibroblast-like cell lines including the 
prostatic fibroblast WPMY-1 but was undetectable from 
THP-1 cells (Fig 2C, right panel). 
Basal expression of CCR2 and CXCR4 was also 
detected in each of the stromal cell lines (Fig S2E). Given 
the effect of CXCL8 in regulating expression and secretion 
of CCL2 and CXCL12 from these stromal cells, we also 
extended our analysis and confirmed that CCR2 (Fig 
Figure 3: CXCL12 signaling potentiates the chemotactic migration of PC3 cells. (A) Representative images of wound scratch 
assays conducted using PC3 monolayers, subjected to treatment with relevant concentrations of CXCL8 and CXCL12, or treatment with 
the CXCR4 inhibitor AMD3100. Images shown depict the uniformity of the wound scratch at time of initiation (t=0) and the resulting 
closure of the wound after 8h stimulation. (B) Bar graph presenting the quantitation of wound closure of a PC3 monolayer resulting from 
various chemokine treatments. Data shown is the mean ± S.E.M. value of three independent experiments, each performed in triplicate. (C) 
Representative images of wound scratch assays conducted using PC3 monolayers, subjected to treatment with relevant concentrations of 
CXCL8 and CCL2. Images shown depict the uniformity of the wound scratch at time of initiation (t=0) and the resulting closure of the wound 
after 6 h stimulation. (D) Bar graphs illustrating the extent of wound closure of the PC3 monolayers promoted by stimulation with CXCL8 
or CCL2, in isolation or in combination (left panel), and the impact of administering a CCR2 antagonist RS102895 upon CCL2-induced 
wound closure (right panel). Data shown is the mean ± S.E.M value, determined from a minimum of 3 replicate experiments. Statistically 
significant differences in expression were determined by performing a two-tailed Students t-test (*p<0.05; ** p<0.01; ***p<0.001).
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2D, left panel) and CXCR4 (Fig 2D, right panel) mRNA 
expression by each of these stromal cell lines was also up-
regulated in response to CXCL8 stimulation.
Our initial data suggests that stromal rather than 
prostate cancer cells are the principal source of CCL2 and 
CXCL12. Moreover, the release of CXCL8 from PTEN-
depleted prostate cancer cells may act in a paracrine 
manner to increase the expression and secretion of CCL2 
and CXCL12 from neighboring stromal cells. In contrast, 
autocrine CXCL8 signaling increases the expression of 
CCR2 and CXCR12 in prostate epithelium but does not 
appear to affect expression of the chemokine ligands. 
Figure 4: Fibroblasts accelerate PC3 cell motility through a CXCR4-dependent mechanism. (A) Left; Representative 
images of wound scratch assays conducted using PC3 monolayers in the presence of WPMY-1 prostate stromal fibroblasts and the impact of 
administering the CXCR4 antagonist AMD3100. Right; Bar graphs presenting the quantification of wound closure observed under various 
treatments in wound scratch assays. Data shown is the mean ± S.E.M. value calculated from 4 independent experiments, each performed 
in duplicate/triplicate. Images shown depict the uniformity of the wound scratch at time of initiation (t=0) and the resulting closure of 
the wound after 6h stimulation. (B) Representative images of wound scratch assays conducted using PC3 monolayers in the presence of 
WPMY-1 prostate stromal fibroblasts and the impact of administering the x1/2pal-i3 pepducin to the co-culture and corresponding bar 
graphs presenting the quantification of wound closure. Data shown is the mean ± S.E.M. value calculated from 4 independent experiments, 
each performed in duplicate/triplicate. (C) Representative images of wound scratch assays conducted using PC3 monolayers in the presence 
of WPMY-1 prostate stromal fibroblasts and corresponding bar graphs presenting the quantification of wound closure. Data shown is 
the mean ± S.E.M. value calculated from 4 independent experiments, each performed in duplicate/triplicate. Images show the effect of 
administering the CXCR4 inhibitor AMD3100 in the absence and presence of the CXCR1/CXCR2-targeted x1/2pal-i3pepducin upon 
the WPMY-1 fibroblast accelerated wound closure of PC3 cells. Statistically significant differences in expression were determined by 
performing a two-tailed Students t-test (*p<0.05; ** p<0.01; ***p<0.001).
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Collectively, this data indicates that CXCL8 signaling may 
initiate signaling that results in increasing the sensitivity of 
prostate epithelium to stromal-derived chemokine signals. 
CXCL8, CCL2 and CXCL12 play differential 
roles in potentiating the chemotactic migration of 
prostate cancer cells
Local tumor migration and invasion plays an 
important role in metastasis and therapeutic relapse. 
To explore the significance of CXCL8-promoted and 
stromal-derived chemokine signaling on prostate 
cancer cell-migration, we established a series of in vitro 
experiments to characterize the functional importance 
of CXCL8, CXCL12 and CCL2 as independent and co-
dependent migratory factors within the prostate tumor 
microenvironment. 
Using wound scratch assays, we observed no change 
in the migratory potential of PC3 cells when stimulated 
with CXCL12 (100ng/ml) or CXCL8 (3nM) alone (Fig 
3A & 3B). However, a significant increase in wound 
Figure 5: Macrophage-promoted acceleration of prostate cancer cell motility is sensitive to CXCR1/CXCR2 inhibition. 
(A) Representative images of wound scratch assays conducted using PC3 monolayers, examining the impact of THP-1 cells upon the 
acceleration of prostate cancer cell motility, in the absence and presence of the CXCR1/CXCR2-targeting x1/2i3-pal and the CXCR4 
inhibitor AMD3100. Images shown depict the uniformity of the wound scratch at time of initiation (t=0) and the resulting closure of the 
wound after 6 h stimulation. (B) Bar graph presenting the quantification of wound closure effected by the addition of THP-1 cells to PC3 
cell monolayers and the impact of administering the CXCR1/CXCR2-targeting x1/2pal-i3pepducin or the CXCR4 antagonist AMD3100 to 
the co-culture. Data shown is the mean ± S.E.M. value calculated from 4 independent experiments, each performed in duplicate/triplicate. 
(C) Bar graphs presenting the quantification of wound scratch assays examining the effect of the CCR2 inhibitor RS102895 on THP-1 (left 
panel) or WPMY-1 (right panel)-induced migration of PC3 cells. Data shown is the mean ± S.E.M. value calculated from 4 independent 
experiments, each performed in duplicate/triplicate. Statistically significant differences in expression were determined by performing a 
two-tailed Students t-test (*p<0.05; ** p<0.01; ***p<0.001).
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closure was observed when PC3 cells were co-stimulated 
with CXCL8 and CXCL12. This migratory response to 
CXCL8 and CXCL12 was abrogated by administration of 
the CXCR4 antagonist AMD3100 (Fig 3A & 3B). 
This co-dependent effect of CXCL8 and CXCL12 
was supported in further experiments. Use of a traditional 
Boyden chamber experiment confirmed that migration 
towards a CXCL12 stimulus (lower chamber) was only 
observed following the addition of CXCL8 to the upper 
chamber of the apparatus (Fig S3, left panel). Moreover, 
experiments conducted over an extended timecourse on 
the Xcelligence platform demonstrated an increased rate 
of migration of CXCL8-stimulated PC3 cells towards 
CXCL12 (Fig S3, right panel). 
In contrast, the effect of CCL2 upon PC3 cell 
migration was more complex. Addition of CCL2 (100ng/
ml) alone significantly enhanced the rate of wound closure. 
However, although CCL2 and CXCL8 together increased 
the migratory potential of PC3 cells over control, the effect 
was not as dramatic as that exerted by CCL2 alone (Fig 
Figure 6: Characterization of the effects of CCL2 and CXCL12 on the proliferation and viability of prostate cancer 
cells. (A) Bar graph presenting cell count data illustrating the effect of administering the CXCR1/CXCR2-targeting inhibitor x1/2pal-i3or 
the CCR2 antagonist RS102895, independently or in combination upon the proliferation of PTEN-deficient PC3 cells. (B) Flow cytometry 
data demonstrating the effect of administering RS102895 upon cell cycle progression (left panel) and cell viability (right panel). (C) 
Bar graph presenting cell count data illustrating the effect of the CXCR4 inhibitor AMD3100 on the proliferation of PC3 cells. (D) Left 
panel; Bar graph presenting the effect of CCL2 (100ng/mL) upon the viability of PC3 cells, transfection-control PC3 cells (PC3-NT) or 
low CXCL8-expressing PC3 cells, assessed by MTT assay. Right panel; bar graph illustrating the effect on cell proliferation affected by 
administering the CCR2 antagonist RS102895 to PC3-NT or low CXCL8-expressing PC3-120 cells in the absence and presence of CCL2 
(100 ng/mL). Statistically significant differences in expression were determined by performing a two-tailed Students t-test or two-tailed 
Mann-Whitney U test (*p<0.05; ** p<0.01; ***p<0.001).
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3C & 3D, left panel). CCL2-promoted PC3 cell motility 
was arrested by the administration of the CCR2 antagonist 
RS102895 (Fig 3D). 
Similar experiments were performed on isogenic 
DU145 clones. We observed a significant increase in 
wound closure when PTEN-expressing DU145 NT.01 
and PTEN-depleted DU145 11.02 cells were cultured 
with CXCL8 in combination with CXCL12(Fig S4), 
eliminating the potential that this response was specific to 
PC3 cells. Thus, our experiments indicate that CXCL8 and 
CXCL12 signaling co-operate to accelerate the migration 
of prostate cancer cells. 
CXCL-8-induced stromal-derived CXCL12 
secretion promotes PC3 cell migration
Co-culture experiments were conducted to examine 
whether CXCL8-induced increases in stromal cell-derived 
CXCL12 expression could potentiate prostate cancer cell 
migration. CXCL8-secreting PC3 cells were co-cultured 
overnight with either THP-1 or WPMY-1 cells prior to 
wound scratch assays, allowing signaling between tumor 
and stromal cells to be established. 
WPMY-1 cells acted to promote the migration of 
PC3 cells (Fig 4A). Addition of the CXCR4-selective 
antagonist AMD3100 significantly attenuated this 
response, confirming the importance of CXCL12/CXCR4 
signaling in enabling this fibroblast-enhanced migration. 
Similarly, inhibition of CXCL8 signaling using a peptide-
based receptor-targeting pepducin (x1/2pal-i3) [22] was 
also shown to significantly attenuate the WPMY-1-induced 
migration of PC3 cells (Fig 4B). In a further series of 
parallel experiments, we observed that while targeting 
either the tumor-derived signaling stimulus, CXCL8 
(using x1/2pal-i3), or the fibroblast-derived enabler 
of migration, CXCL12 (using AMD3100), attenuated 
the migration of PC3 cells to similar extents, a trend 
towards more effective attenuation of WPMY-1-promoted 
wound closure was observed following the simultaneous 
administration of both AMD3100 and x1/2pal-i3 (Fig 4C). 
Addition of THP-1 cells also promoted PC3 
wound closure (Fig 5A/B). Interestingly, this response 
was inhibited by addition of x1/2pal-i3 pepducin while 
administration of AMD3100 had no effect, consistent 
with our observation that THP-1 cells do not secrete 
detectable levels of CXCL12. Addition of the CCR2 
inhibitor RS102895 attenuated both THP-1- and WPMY-
1-promoted migration of PC3 cells (Fig 5C), consistent 
with the secretion of CCL2 from each of these stromal 
Figure 7: Schematic diagram representing chemokine crosstalk within the tumor microenvironment. 1. Autocrine 
CXCL8 signaling results in the up-regulation of CXCR1, CXCR2, CXCR4 and CCL2 on the tumor cells. 2. Paracrine CXCL8 signaling 
leading to the up-regulation of CXCR1, CXCR2, CXCR4 and CCR2 expression by tumor-associated stromal cells. Paracrine CXCL8 
signaling also induces secretion of CCL2 by macrophages and fibroblasts, as well as CXCL12 secretion by tumor-associated macrophages.
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cells.
CXCL8, CXCL12 and CCL2 have differential 
impacts on the proliferation and survival of 
prostate cancer cells.
We investigated the role of CXCL8, CCL2 and 
CXCL12 in regulating the growth and survival of 
prostate cancer cells, independently or in a co-dependent 
manner. Stimulation of PC3 cells with CCL2 resulted in a 
concentration-dependent increase in the proliferation rate. 
In contrast, stimulation with increasing concentrations of 
CXCL12 inhibited the proliferation rate of PC3 cells (Fig 
S5A). Accordingly, further experiments investigated the 
importance of stromal-derived CCL2 signaling on prostate 
cancer cell proliferation/viability. 
Treatment with the CCR2 antagonist RS102895 
significantly reduced the viability of PC3 cells in both a 
cell count assay (Fig 6A) and a MTT assay (Fig S5B). 
Cell cycle analysis demonstrated a significant increase 
in the percentage of cells in the G2/M phase of the cell 
cycle following administration of RS102895 (Fig 6B, left 
panel). However, inhibition of CCL2 signaling using this 
antagonist did not increase the level of apoptotic cells 
detected by PI/annexin V-labelling (Fig 6B, right panel). 
Consistent with our published reports, the inhibition of 
CXCL8 signaling using x1/2pal-i3 similarly reduced 
the viability of PTEN-depleted PC3 cells (Fig 6A & Fig 
S5B). However, we observed no additional benefit from 
co-administering RS102895 and x1/2pal-i3 in the context 
of reducing cell viability (Fig 6A). As further internal 
validation of our data, treatment with the CXCR4 inhibitor 
AMD3100 had no effect on basal cell number relative to 
untreated controls or in affecting the viability of the PC3 
cells in MTT assays (Fig 6C & Fig S5B). 
Autocrine CXCL8 signaling augments sensitivity 
of PC3 cells to CCL2 stimulation
Elevated CXCL8 expression and the 
characterization of autocrine signaling effects of CXCL8 
in PC3 cells is well-documented [20,23]. We developed 
further derivative PC3 models to investigate how the 
levels of autocrine CXCL8 signaling may augment the 
ability of CCL2 to enhance cell proliferation. PC3 cells 
were transfected with a CXCL8-targeted shRNA. While 
transfection protocols with shRNA did result in the loss 
of PC3 viability, we were able to select a small number 
of residual populations; CXCL8 expression within the 
selected populations was characterized by qPCR analysis 
and ELISA. For the purpose of this study, a population 
with CXCL8 expression equivalent to parental PC3 cells 
(PC3-NT) and a population in which CXCL8 expression 
was repressed by ~25% relative to PC3-NT levels (PC3-
120; Fig S5C) were used in further experimentation. 
Consistent with our earlier results indicating that CXCL8 
signaling up-regulated CCR2 and CXCR4 expression 
in prostate cancer cells, we observed that the reduction 
in autocrine CXCL8 expression resulted in a significant 
decrease in CCR2 and CXCR4 mRNA expression in PC3-
120 cells (Fig S5C). Growth curve analysis demonstrated 
that there was no significant difference in the basal growth 
rate observed between parental PC3, PC3-NT and PC3-
120 cells (Fig S5D). Stimulation of PC3-NT cells with 
rh-CCL2 promoted cell proliferation to a similar extent 
as observed in parental PC3 cells (Fig 6D, left panel). 
In contrast, CCL2 had no effect on growth of the low 
CXCL8-expressing PC3-120 cells (Fig 6D, left panel). 
Addition of RS012895 attenuated CCL2-promoted 
growth of PC3-NT cells, but there was no effect on the 
proliferation of PC3-120 cells (Fig 6D, right panel). 
DISCUSSION
PTEN-deficiency is a major molecular hallmark 
of prostate cancer [4]. We have associated increased 
expression and secretion of the pro-inflammatory CXC-
chemokine CXCL8 with loss of PTEN function in prostate 
cancer cells and prostatic tissue [20]. Furthermore, loss 
of PTEN function concurrently increased the expression 
of CXCL8 receptors (CXCR1 and CXCR2), with the 
resulting elevated autocrine CXCL8 signaling acting 
to sustain the viability of these PTEN-deficient prostate 
cancer cells [20]. Beside their elevated expression in 
PTEN-deficient prostate cancer cells, CXCR1 and CXCR2 
are also expressed on vascular endothelial cells, monocytes 
and fibroblasts [24,25]. Therefore, each of these cell 
types within the tumor microenvironment is potentially 
receptive to the increased levels of CXCL8 secreted by 
PTEN-deficient prostate cancer cells. The objective of 
this study was to characterize the functional importance, 
and molecular basis, of CXCL8-promoted tumor-stromal 
communication in promoting the aggressiveness of PTEN-
deficient prostate cancer cells, with a specific focus on 
understanding how tumor-derived CXCL8 may regulate 
the expression of stromal-derived chemokines. 
Our data highlights a co-ordinated response of 
tumor and stromal cells to the secretion of CXCL8 
from malignant prostate cancer cells. Autocrine CXCL8 
signaling was shown to-upregulate the expression of 
chemokine receptors in prostate cancer cells. Interestingly, 
CXCL8 signaling increased the expression of CXCR1 
and CXCR2 receptors in PTEN-deficient prostate cancer 
cells, suggesting that CXCL8 signaling acts in a self-
sustaining capacity, to potentiate its signaling in PTEN-
deficient prostate cancer. Furthermore, CXCL8 signaling 
also increased the expression of CXCR4 and CXCR7 (the 
receptors mediating the biological activity of CXCL12) 
and CCR2 (a receptor activated by the ligand CCL2) 
in both PTEN-expressing and PTEN-deficient prostate 
cancer cells. 
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While CXCL8 was unable to induce chemokine 
synthesis in prostate cancer cells, CXCL8 signaling 
did increase CXCL12 and CCL2 synthesis in prostate 
stromal fibroblasts and monocytes. Elevated CXCL12 
secretion was observed from cells of fibroblast origin 
while increased CCL2 secretion was demonstrated 
in fibroblasts and monocytes. CXCL8 signaling also 
increased CXCR4 and CCR2 expression in these stromal 
cells. Although we have not investigated the significance 
of these concurrent increases in chemokine ligand and 
receptor expression upon the function of the stromal 
cells themselves, it is conceivable that this elevated 
chemokine signaling may regulate stromal cell function. 
For example, CCL2 is known to drive the differentiation 
of macrophages towards the M2 phenotype [26], typically 
associated with a tumor progression. Moreover, CCL2 can 
drive the infiltration of lymphocyte populations [27]. We 
propose that, in addition to immediate impacts on tumor 
cells, tumor-derived CXCL8 may also initiate sustained, 
long-term effects on the tumor microenvironment, by 
activating resident stromal cells, which, in turn, may 
act to either directly remodel the tumor site or promote 
the recruitment of additional cell types. Previous studies 
have also demonstrated the importance of fibroblast-
derived CXCL12 in the evasion of immunosurveillance 
in pancreatic ductal adenocarcinoma [28]. Our current 
findings propose that tumor-derived CXCL8, through the 
regulation of fibroblast-derived CXCL12 production, may 
drive immune evasion in prostate cancer.
CXCL8 did not promote migration of prostate 
cancer cells; elevated secretion of CXCL8 by prostate 
tumors results in locally high levels of this chemokine 
which in turn may prevent the establishment of a 
chemotactic CXCL8 gradient. Instead, integrating our 
observations in tumor and stromal cell lines, we propose 
that tumor-derived CXCL8 signaling initiates a co-
ordinated chemokine-driven cross-talk between tumor 
and stromal cells (Fig 7). Our data demonstrates that 
tumor-derived CXCL8 acts to increase the secretion of 
stromal-derived chemokines which then activate the 
increased pool of their respective receptors expressed 
on the surface of prostate cancer cells. Ultimately, the 
combined effect is that CXCL8 signaling increases the 
sensitivity of prostate cancer cells to stromal-derived 
chemokines. Our functional experiments establish that 
CXCL12 and CCL2 act upon prostate cancer cells to 
induce very different responses. While CXCL12 was 
clearly implicated in supporting fibroblast-dependent 
migration of PC3 cells, CCL2 signaling was observed to 
be more effective in underpinning monocyte-dependent 
proliferation of the malignant cells. For either of these 
phenotypes, we observed that the efficacy of the stromal-
derived chemokine required the presence of tumor-derived 
CXCL8 signaling (Fig 7). For example, in migration 
assays, addition of both CXCL8 and CXCL12 was 
necessary in order to observe migration. Furthermore, PC3 
cells expressing lower levels of CXCL8 were insensitive 
to the proliferation-promoting effects of CCL2. We 
propose these results indicate the importance of CXCL8-
driven CXCR4 and CCR2 expression in the prostate 
cancer cells, which increases their capacity to respond to 
each of these stromal-derived chemokines. 
Addition of fibroblasts and macrophages promoted 
the migration and invasion of PC3 cells. CXCL12/
CXCR4 signaling was shown to support fibroblast-
mediated migration and invasion of PC3 cells in co-
culture assays but not that promoted by macrophage-like 
cells. Moreover, combined inhibition of both CXCL8 
and CXCL12 signaling was more effective in repressing 
fibroblast-promoted cell motility. In contrast, although 
CCL2 signaling had only a minor effect on macrophage-
induced prostate cancer cell motility, this chemokine had 
significant effects upon the proliferation and survival 
of PTEN-deficient prostate cancer cells. Furthermore, 
repression of CXCL8 signaling reduced the sensitivity 
of prostate cancer cells to these effects of CCL2. These 
observations have important considerations in the context 
of chemokine signaling as therapeutic interventions. 
Specifically, our data suggests that targeting of only 
one chemokine signaling axis may not be sufficient to 
adequately suppress independent functional responses. 
Furthermore, given the interplay between tumor-derived 
and stromal-derived chemokines, we propose that co-
targeting of multiple chemokine pathways may be 
required in order to diminish multiple behavioral traits 
of aggressive PTEN-deficient prostate cancer cells. 
Therefore, combined targeting of CXCR1/CXCR2, 
CXCR4 and CCR2 signaling may be necessary in order to 
deliver concurrent inhibition of stroma-promoted invasion 
and proliferation. 
In summary, we report the characterization of a 
CXCL8-driven augmentation of CXCL12 and CCL2 
signaling arising from different compartments of the 
tumor-associated stroma, which act to sustain the 
hallmarks of increased cell motility (migration and 
invasion) and increased cell proliferation and survival. 
Our study complements prior studies which have reported 
the significance of stromal-derived CXCL12 signaling in 
driving the invasion and metastasis of prostate cancers 
[14,29], and provides a more-detailed understanding 
of how stromal-derived chemokine signaling may be 
induced. We propose this chemokine cross-talk has 
greatest relevance to foci of PTEN-deficient prostate 
cancers which secrete higher levels of CXCL8 in order 
to trigger the induction of stromal chemokine synthesis. 
Dedicated studies employing immune-competent 
transgenic models of PTEN-deficient prostate cancer are 
underway in our laboratory to provide greater insight into 
the potential consequences of this chemokine signaling 
cross-talk in driving the aggressiveness of PTEN-deficient 
prostate carcinomas.
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MATERIALS AND METHODS
Chemical and Reagents
Chemicals were source from Sigma-Aldrich (St. 
Louis, MO) unless otherwise stated.
Cell Culture and Treatments
Prostate cancer cell lines (PC3, DU145, LNCaP 
and 22Rv1) or clones were sourced, derived and 
cultured as previously described [20]. Fibroblast (293T, 
human embryonic kidney; WPMY-1, prostate stroma) 
cell lines were maintained in DMEM (GE Healthcare, 
Buckinghamshire, UK) supplemented with 10% (v/v) fetal 
calf serum (FCS; GIBCO BRL/Life Technologies, Paisley, 
Scotland). Human macrophage-like THP-1 cells were 
maintained in RPMI supplemented with 10% FCS and 
0.05M β-mercaptoethanol. All cell lines were maintained 
at 37oC.
In experiments investigating CXC-chemokine 
signaling, cells were incubated in serum-free, phenol-
red free RMPI 1640 or DMEM medium for 16h prior to 
exposure to 3nM recombinant human (rh)-CXCL8, 100ng/
ml rh-CXCL12 or 100ng/ml rh-CCL2 (Peprotech, London, 
UK). For inhibition of chemokine signaling, cells were 
treated with RS102895 (CCR2 antagonist, 10nM; Tocris, 
Bristol, UK), AMD3100 (CXCR4 antagonist, 25µg/ml; 
Tocris) or a CXCR1/2-derived pepducin (x1/2pal-i3, 
300nM; Biomatik, Wilmington, Delaware). Control cells 
were treated with the appropriate vehicle or NT-pepducin 
(x1/2pal-con) sequence as required.
Generation of PC3-120 cells
CXCL8-depleted PC3-120 and corresponding PC3-
NT cells were generated by stable downregulation of 
CXCL8 using commercially available CXCL8-targeted 
shRNA and non-targeting plasmids (HuSH constructs 
in pGFP-V-RS vector; Origene, Rockville, MD, USA) 
according to the manufacturer’s instructions. Briefly, 
PC3 cells (5 x 105) were incubated in a transfection 
mix containing plasmid (2μg), Lipofectamine 2000 and 
OptiMEM medium (GIBCO BRL/Life Technologies). 
Following 24h, cells were reseeded and populations 
containing the shRNA plasmids were selected using 
puromycin (0.5μg/ml). PC3-NT and PC3-120 cells were 
maintained in RPMI 1640 medium supplemented with 
10% FCS and 0.5μg/ml puromycin.
Quantitative real time PCR (qPCR)
RNA was harvested and reverse transcribed as 
previously described using specified primer sequences 
[20]. Real-time PCR was performed in 96-well plates 
using an LC480 light cycler instrument (Roche 
Diagnostics, Burgess Hill, UK). MRNA expression levels 
were determined using the relative standard curve method 
and normalized against 18S. 
Immunoblotting
Whole cell lysates were prepared, resolved and 
blotted as described previously [20]. CXCR4 expression 
was detected using an anti-human CXCR4 antibody 
(Abcam) at 1:1000. Expression of CXCR1 and CXCR2 
were detected as previously described [30]. Membranes 
were re-probed with GAPDH antibody to ensure equal 
loading (Biogenesis, Dorset, UK).
ELISA
The amount of secreted CCL2 (Biolegend, London, 
UK) or CXCR12 (R&D systems, Abringdon, UK) detected 
in the medium of prostate cancer cells was determined 
using an ELISA assay according to the manufacturer’s 
instructions. 
MTT Assay and Cell Count Analysis
Cells were plated and treated with chemokines or 
chemokine inhibitors for 48h or 72h as required. Cell 
number was assessed by Coulter Counter [30] while cell 
viability was assessed by MTT assay [31]. 
Cell cycle Analysis
PI staining and cell cycle analysis was performed as 
previously described [30].
Apoptosis Assay
Apoptosis was measured as previously described 
[20]. 
Migration Assays
Wound scratch assays were performed on confluent 
monolayers of prostate cancer cells. Prostate cancer cells 
were treated and/or co-cultured with stromal cell lines 
as required prior to a regular scratch being made in the 
prostate cell monolayer. Plates were observed and imaged 
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using Cell B software (Olympus; Southend-on-Sea, UK) 
incubated for the required length of time and imaged 
again. Wounds were measured using ImageJ software and 
the degree of wound closure calculated.
Migration assays were performed on uncoated 
transwell membranes (12µM pore size; CoStar). Cells 
were seeded with media alone or stimulated with media 
containing 3nM CXCL8 and allowed to migrate towards 
media alone or media containing 100ng/ml CXCL12 for 
20h before the membranes were stained with crystal violet 
and the absorbance of each well calculated. 
Cell movement through a synthetic matrix in vitro 
was assessed using the RTCA DP cell analyzer system 
(Roche Diagnostics, Mannheim, Germany). The upper 
chamber of CIM invasion plates were pre-coated with 
MatrigelTM (5% in SFM). Cells were stimulated with 3nM 
CXCL8 as required and invasion towards media alone or 
media containing 100ng/ml CXCL12 was investigated. 
Measurements were taken every 15min for 36h.
Statistical Analysis
Two-tailed Mann-Whitney U-test or a Student’s 
t-test was used to compare means where appropriate. 
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